HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

President signs JOBS bill

This article was originally published in The Tan Sheet

Executive Summary

Multinational pharma, dietary supplement and nutritional product manufacturers will pay a reduced tax rate for repatriated foreign earnings after President Bush signed the legislation into law on Oct. 22. The bill cuts the repatriation tax rate from 35% to 5.25%, giving firms an incentive to repatriate earnings in the U.S. (1"The Tan Sheet" Oct. 18, 2004, p. 7). In an Oct. 29 earnings call, Schering-Plough CFO Bob Bertolini called the legislation "a very positive development" that will provide added financial flexibility, but noted it is "too early" to speculate how much of the firm's $9 bil. in undistributed foreign earnings will be repatriated...

You may also be interested in...



Pharma Firms Ready To Repatriate Billions Once “JOBS” Bill Is Signed

J&J intends to repatriate as much as $10 bil. held by foreign subsidiaries following President Bush's expected signing of the "JOBS" bill

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Topics

UsernamePublicRestriction

Register

RS128408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel